losartan has been researched along with Experimental Mammary Neoplasms in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, L | 1 |
| Chen, D | 1 |
| Wang, R | 2 |
| Zhang, H | 1 |
| Zhang, Z | 1 |
| Nie, Z | 1 |
| Lu, S | 1 |
| Li, W | 1 |
| Li, S | 1 |
| Chen, IX | 1 |
| Liu, Y | 2 |
| Ramjiawan, RR | 1 |
| Leung, CH | 1 |
| Gerweck, LE | 1 |
| Fukumura, D | 1 |
| Loeffler, JS | 1 |
| Jain, RK | 2 |
| Duda, DG | 1 |
| Huang, P | 2 |
| Coulson, R | 1 |
| Liew, SH | 1 |
| Connelly, AA | 1 |
| Yee, NS | 1 |
| Deb, S | 1 |
| Kumar, B | 1 |
| Vargas, AC | 1 |
| O'Toole, SA | 1 |
| Parslow, AC | 1 |
| Poh, A | 1 |
| Putoczki, T | 1 |
| Morrow, RJ | 1 |
| Alorro, M | 1 |
| Lazarus, KA | 1 |
| Yeap, EFW | 1 |
| Walton, KL | 1 |
| Harrison, CA | 1 |
| Hannan, NJ | 1 |
| George, AJ | 1 |
| Clyne, CD | 1 |
| Ernst, M | 1 |
| Allen, AM | 1 |
| Chand, AL | 1 |
| Tang, Y | 1 |
| Wang, S | 1 |
| Tian, Y | 1 |
| Li, Y | 1 |
| Teng, Z | 1 |
| Lu, G | 1 |
| Chauhan, VP | 1 |
| Martin, JD | 1 |
| Liu, H | 1 |
| Lacorre, DA | 1 |
| Jain, SR | 1 |
| Kozin, SV | 1 |
| Stylianopoulos, T | 1 |
| Mousa, AS | 1 |
| Han, X | 1 |
| Adstamongkonkul, P | 1 |
| Popović, Z | 1 |
| Bawendi, MG | 1 |
| Boucher, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)[NCT03513198] | 200 participants (Anticipated) | Observational | 2018-05-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for losartan and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Transformable Honeycomb-Like Nanoassemblies of Carbon Dots for Regulated Multisite Delivery and Enhanced Antitumor Chemoimmunotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Carbon; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Dru | 2021 |
Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chemoradiotherapy; Female; Losartan; Lung Neoplasm | 2021 |
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiotensin II Type 1 Receptor Blockers; Animals; Biopsy; Breast N | 2017 |
Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chlorophyllides; Collagen Type I; Female; Losartan; Male; | 2019 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |